🇺🇸 FOLFIRI + cetuximab in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bladder Injury — 1 report (10%)
  2. Colorectal Cancer Metastatic — 1 report (10%)
  3. Death — 1 report (10%)
  4. Dysphonia — 1 report (10%)
  5. Fatigue — 1 report (10%)
  6. Hydronephrosis — 1 report (10%)
  7. Metastases To Abdominal Cavity — 1 report (10%)
  8. Metastases To Bone — 1 report (10%)
  9. Metastases To Liver — 1 report (10%)
  10. Metastases To Lung — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is FOLFIRI + cetuximab approved in United States?

FOLFIRI + cetuximab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for FOLFIRI + cetuximab in United States?

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) is the originator. The local marketing authorisation holder may differ — check the official source linked above.